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C Ulivieri6, P Tagliaferri5, MG Cusi4, M Caraglia2 and P Correale1
The mPEBev is an anticancer regimen which combines a chemotherapy doublet, based on cisplatin and oral etoposide (mPE), with
bevacizumab (mPEBev), a mAb targeting the vasculo-endothelial growth factor (VEGF). In previous studies, this regimen showed
powerful anti-angiogenetic effects and significant antitumor activity in metastatic non-small-cell lung cancer (mNSCLC) patients.
We also recorded the best benefit in patients exhibiting low-systemic inflammatory profile at baseline. On these bases, we
hypothesized that mPEBev antitumor activity could be partially related to bevacizumab-associated immunological effects. For this
reason, we performed an immunological monitoring in 59 out of 120 stage IIIb-IV NSCLC patients enrolled in the BEVA2007 phase II
trial, who received fractioned cisplatin (30 mg/sqm days 1-3q21) and oral etoposide (50 mg, days 1-15q21) (mPE doublet)
± bevacizumab. In this group of patients, 12 received the mPE doublet alone and 47 the doublet in combination with bevacizumab
(5 mg/kg on the day 3q21; mPEBev regimen). Blood cell counts, serum analysis, multiplex cytokine assay and
immunocytofluorimetric analysis, performed on baseline and post-treatment on blood samples from these patients, revealed that
bevacizumab addition to the doublet decreased levels of pro-angiogenic (VEGF, Angiostatin-1 and Follistatin) and inflammatory
cytokines (interferon (IFN)γ, IL4 and IL17), improved in vivo and in vitro cytotoxic T-lymphocytes (CTL) response and promoted
dendritic cell activation. These results suggest that the mPEBev regimen improve the micro-environmental conditions for an
efficient antigen-specific CTL response, making it a feasible candidate regimen to be assessed in combination with immune-
checkpoint inhibitors in NSCLC patients.
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Non-small-cell lung cancer (NSCLC) is the most common
malignancy and the leading cause of cancer death worldwide.1
The majority of NSCLC patients who cannot undergo curative
surgery and who are diagnosed with advanced disease, have a
poor prognosis with a survival time that usually does not exceed
8–10 months.2 The standard treatment for metastatic (m) NSCLC
patients is based on doublets of platinum derivatives in
combination with a second cytotoxic drug,2,3 or molecular
target-specific inhibitors for patients presenting activating EGFR
mutations (Erlotinib, Gefitinib and Afatinib) or EML-ALK transloca-
tions (Crizotinib, etc.).4,5 The efficacy of poly-chemotherapy in
non-squamous NSCLC has been further improved by a multidrug
combination with bevacizumab, a humanized IgG1 to the vascular
endothelial growth factor (VEGF).6,7 More recently, active immu-
notherapy and immune-checkpoint inhibitors are entering in the
treatment of mNSCLC. In particular, two monoclonal antibodies
(mAbs), Nivolumab and Pembrolizumab, have shown evidence of
antitumor activity in these patients.8–13 Nivolumab and Pembro-
lizumab are two mABs directed to the programmed cell death
receptor (PD)1, commonly expressed on activated antigen-specific
cytotoxic T lymphocytes (CTLs), residual of a pre-existing tumor-
specific immune-response.8–13 PD1 binding with its specific
ligands (PDL-1 and 2) in tumor tissue, leads to the immediate
deactivation of the effector cells8–13 and, therefore, it represents a
powerful inhibitory immune-checkpoint and a formidable
mechanism of immune-escape for cancer cells.8–13 In this context,
it has been shown that the VEGF deprivation induced by
bevacizumab may stimulate immunological alterations, which
could contribute to enhance the efficacy of chemotherapy and the
survival of cancer patients.14–18 In fact, VEGF is a soluble dimeric
protein family with multiple bio-regulative activities, mainly
released in hypoxic and inflammatory conditions by mature
granulocytes and platelets.19–22 It is worldwide known for its
ability in inducing endothelial proliferation, neo-vessel formation
and normalization in cancer patients; however, its bio-regulative
activity is very pleyotropic and complex, and also involves the
anticancer immune-system. In fact, its effects are mediated
throughout the binding to five different membrane receptors,
which are, in turn, expressed on endothelial precursors and other
cell lineages including myeloid precursors, dendritic cells (DCs),
lymphocytes and mesencephalic neurons.19–22 Therefore, VEGF
release might exert multiple and different functions, including
both neutrophils’ and inhibitory myeloid cells’ maturation, as well
as inhibitory effects on DC maturation and CTL precursors’
activation.14–18 We have previously designed a phase I/II clinical
trial (BEVA 2007 study) aimed to investigate the toxicity and the
biological and antitumor activity of a novel metronomic bio-
chemotherapy regimen (mPEBev) in mNSCLC patients. This
regimen combined a previously described mPE doublet of
cisplatin and oral etoposide, with bevacizumab (Bev). Our
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preliminary results showed that the addition of bevacizumab
to the metronomic doublet was safe and very active in term
of antitumor activity.23–26 We also found that the mPEBev
administration was followed by a rapid decline in the primary
tumor blood flux (perfusional CT scan)25 paralleled by a sign-
ificant decline in VEGF, angiopoietin-1, thrombospondin-1 serum
levels25 and systemic inflammatory markers (NLR, CRP, LDH and
myeloperoxidase).23–26 An additional study carried out by our
group, demonstrated that the best advantage on progression-free
survival and overall survival were recorded in patients who
presented a lower systemic inflammatory profile before the
beginning of the treatment.27 These findings suggested that
bevacizumab and, therefore, VEGF deprivation could synergize
with the cytotoxic drug doublet through different mechanisms:
(i) direct anticancer effects, (ii) anti-angiogenetic activity and
(iii) immune-modulating activity. On these bases, with the present
study we have evaluated immunological alterations in serum and
peripheral blood mononuclear cells (PBMCs) derived from 59
patients who had received mPE doublet ± bevacizumab from
September 2012 to May 2015. We also performed a fuctional
ex vivo study on antigen-specific T-cell lines generated from




The BEVA2007 was a phase II trial, designed on translational bases
and approved by the Siena University Ethical committee on March
2007. It was performed to assess toxicity, biological activity and
antitumor activity of the mPE doublet ± bevacizumab in mNSCLC
patients. One-hundred and fifteen, stage IIIb-IV NSCLC, patients
signed an informant consent and were enrolled in the BEVA2007
trial since April 2007. All of them received the chemotherapy
doublet, alone (30 patients; PE group) or combined with
bevacizumab (85 patients; mPEBev group). We subsequently
performed a pre-ordered immune-biological investigation, on the
peripheral blood of 59 (51%) of these patients. Twelve out 59
patients had received the mPE doublet alone, whereas 47 had
received the doublet combined with bevacizumab (mPEBev).
Blood cell counts, serum analysis, multiplex assays and flow
cytometry analysis were performed on blood samples isolated at
baseline and after two and four treatment courses. The clinical
features of these patients are shown in the Table 1.
Pro-angiogenic factors
Our multiplex assays detected a significant decline in the serum
levels of multiple pro-angiogenic factors in the group of patients
who received the mPEBev regimen, where it was found a
significant decrease in VEGF (early event), angiopoietin-2 and
follistatin (late events). For these patients, we were unable to
demonstrate any significant change in the levels of other factors
potentially involved in both tumorigenesis and neo-angiogenesis,
such as HGF, PECAM-1, Leptin, PDGF-BB, G-CSF and IL8 (Figure 1).
Inflammatory cytokine release
We performed, in the same patients, an additional multiplex assay
to detect possible treatment-associated changes in serum levels of
cytokines involved in different immunological and inflammatory
profiles. We found a significant decrease of IFNγ (Th1), IL4 (Th2)
and IL17 (Th17) levels only in the group of patients who received
the bevacizumab-based treatment and not in those who received
the mPE doublet. The latter group of patients, conversely, showed
a trend to increase IL8 and IFNγ levels, even though without
reaching statistical significance. Finally, both groups of patients
showed a trend to increase IL10 and G-CSF levels, also in this case,
without reaching statistical significance (Figure 2).
Immunocytofluorimetric analysis
A multicolour flow cytometry study was carried out on the PBMCs
from these patients, showing a parallel and coordinate increase in
activated (CD8+CD62L+), central-memory (CD8+C45RA−CCR7+;
Tcm) and long-term memory (CD8
+C45RA−CCR7+CD27+) CTLs; a
trend to increase regulatory T cells (Treg) was recorded only in
patients who received the mPEBev regimen. On the other hand,
patients who received the metronomic doublet alone; showed a
significant increase in Tcms (Figure 3a). In this set of patients, both
treatment regimens did not induce significant changes in the
levels of CD3+CD4+, CD3+CD8+ and natural killer cells (CD3-CD16+
CD56+;NK) cells (P40.05).
In PBMcs we also evaluated the effects of treatments on
professional antigen-presenting cells, like DCs and myeloid
derivative inhibitory cells (MDICs). We found that only mPEBev
treatment, was associated with a significant increase in the
Table 1. Patients enrolled in the BEVA2007 trial undergone the
immune-biological monitoring
mPE mPEBev
Patient number 12 47
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Figure 1. A multiplex analysis concerning the dosage of multiple
pro-angiogenetic factors in the serum of mNSCLC patients enrolled
in the BEVA2007 trial who have received the mPE doublet alone ( )
or combined with bevacizumab ( ). Results are expressed as fold
induction relative to baseline indicated as 1 (± S.E.). Asterisks
represent statistical significance to the correspondent baseline
values (*Po0.05; **Po0.01).
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percentage of activated DCs (CD3−CD19−CD11c+CD14+CD15−),
expressing either CD83 or CD80. Conversely, an increasing trend,
even if not significant, was observed in the percentage of
activated MDICs (CD11b+CD14+CD15+) in both groups of patients
(Figures 3b and 4).
Ex vivo characterization of patients-derived antigen-specific
T-cell lines
We performed an ex vivo study on PBMCs isolated from patients
at the baseline and after four treatment courses with mPE
(four patients) or mPEBev (four patients), to verify whether these
regimens were able to interfere with the generation of active
antigen-specific CTLs. We evaluated multiple T-cell functions
which could be potentially affected by the metronomic doublet
± bevacizumab. Thus we cyclically stimulated ex vivo PBMCs
collected from patients with three antigens with completely
different features: (i) streptococcal-B-superantigen (SEB), a bacter-
ial antigen able to over-stimulate both CD3+CD8+ and CD3+CD4+
subsets;28 (ii) immune-reconstituted influenza virosome (IRIV), an
antigenic influenza virus membrane envelope, expressing high-
immunogenic flow antigens and multiple T helper epitopes29 and
(iii) thymidylate synthase poly-epitope peptide vaccine (TSPP), a
27-mer peptide which assembles multiple class I-HLA restricted
CTL epitopes of the thymidylate synthase, a tumor-associated
enzyme commonly overexpressed in colo-rectal and NSCLC cancer
patients.30 TSPP was tested in previous preclinical studies showing
the ability of generate an efficient antitumor in vitro CTL response,
both in mice and in cancer patients.31,32
After multiple in vitro stimulations (IVSs), we evaluated the
percentage of proliferative T cells (CD3+CD8+Ki67+) and Th1/Th2
cytokine release in response to the three antigens. In our setting,
Figure 3. A flow cytometric analysis concerning the expression of (a) different T-cell subsets and (b) myeloid derivative cells (activated DCs
and MDICs) in the PBMCs of mNSCLC patients enrolled in the BEVA2007 trial who have received the mPE doublet alone ( ) or combined with
bevacizumab ( ). Results are expressed as fold induction relative to baseline indicated as 1 (± S.E.). Asterisks represent statistical significance
to the correspondent baseline values (*Po0.05; **Po0.01).
Figure 2. A multiplex analysis concerning the dosage of Th1
(IFNɣ, TNFα and IL12), Th2 (IL4 and IL10), Th17 and inflammatory
cytokines (IL8 and G-CSF) in the serum of mNSCLC patients enrolled
in the BEVA2007 trial who have received the mPE doublet alone ( )
or combined with bevacizumab ( ). Results are expressed as fold
induction relative to baseline indicated as 1 (± S.E.). Asterisk
represents statistical significance to the correspondent baseline
values (*Po0.05).
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the T-cell lines derived from PBMCs isolated at the baseline,
showed a minimal proliferative response to the three antigens
(data not shown and Figure 5a). On the other hand, T-cell lines
derived from PBMCs isolated after four treatments courses,
showed a minimal proliferative response to TSPP and SEB (data
not shown) and a higher response to IRIV (Figure 5a). Moreover,
we observed a greater percentage of proliferative antigen-specific
precursors in T-cell lines derived from patients receiving the
mPEBev regimen, compared with the others (fold change to
baseline values, mPE versus mPEBev = 2.2 (±0,55) versus 4. 1 (±0,4),
P= 0.049; Figure 5a). The functional antigen-specific cytokine
response of these T-cell lines also showed a powerful Th1 response
with parallel tumor necrosis factor (TNF)α and IFNγ release, only in
T cells derived from both mPEBev-treated patients and normal
donors. Furthermore, there was no different response to the three
antigens used for each specific T-cell line in vitro sensitization
(Figures 5b–d). These experiments also showed that T cells
derived from the mPEBev-treated patients had a greater IL10
release in response to IRIV and TSPP. On the other hand, patients
receiving the chemotherapy doublet alone, prevalently showed a
non-cytotoxic Th2 immune-response with an increased antigen-
specific release of IL4 (Figures 5b–d).
DISCUSSION
In the present manuscript, we report the results of an
immunological study performed on 59 patients, enrolled in the
BEVA2007 trial, who received frontline treatment according to
the mPE doublet ± bevacizumab. We show that the addition of
the mAb to the chemotherapy in mNSCLC patients, as partially
observed in our previous studies,23–26 decreases their systemic
inflammatory status and promotes anticancer immune-
modulating effects. In fact, we found that the mPEBev regimen
causes, in patient's serum, significant reduction in the levels of
VEGF and other anti-angiogenetic factors, including Angiopietin 2
and Follistatin, an inhibitor of both TGF-β superfamily activin and
FGF-2R angiogenesis inducer.33 These events were paralleled by a
progressive decline in NLR (data not shown),26 and IFNγ, IL4 and
IL17 serum levels. All together these cytokines are expression of
cancer-associated systemic inflammation, that is paralleled by
immune-suppression and neo-angiogenesis;26,34–38 therefore, it is
possible to hypothesize that a parallel and progressive reduction
of pro-angiogenic factors can have a role in the ultimate antitumor
effects of the mPEBev regimen. Bevacizumab is commonly
considered an anti-angiogenic agent because it subtracts free
VEGF that, in turn, promotes endothelial precursors’ recruitment
and neo-angiogenesis in tumor tissues. However, it has to be
considered that VEGF effects are not limited to endothelial cells. In
fact, VEGF is not produced only by tumor, but it is also transported
to tumor tissues by platelets and inflammatory cells (i.e.:
neutrophils and monocytes) during cancer-associated inflamma-
tion and hypoxic status.18–22 VEGF, in addition, promotes
activation and differentiation of neutrophils, monocytes and
MDICs, and impairs the immune-system by affecting DCs and
specific T-cell subsets.18,22 These findings support the hypothesis
that a systemic inflammation state at the baseline (before the
beginning of treatment) is strongly predictive of poor prognosis
in cancer patients receiving bevacizumab and/or other
immunological-based treatments. Moreover, it has also been
reported that IL17, a pro-inflammatory cytokine produced by Th17
subsets upon stimulation by IFNγ, promotes immune-suppressive
chronic inflammation that can be present in both auto-immune
diseases and cancer. In fact, IL17 attracts neutrophils, myeloid
derivative inhibitory cells and increases VEGF levels in tumor
micro-environment. High IL17 levels are strictly involved in
tumorigenesis, metastatization and in promotion of VEGF-
independent neo-angiogenesis in different malignant diseases.
In the case of lung cancer development, IL17 serum levels
Figure 4. Flow cytometry dot plots of two representative patient PBMCs: activated DCs, isolated at the baseline (a and b) and after four
treatment courses with mPE doublet and bevacizumab (c and d).
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correlate to poor prognosis and serum VEGF levels.37 Moreover,
IL17 promotes angiogenesis by stimulating VEGF production of
NSCLC cells via the STAT3/GIV signaling pathway.38 The results of
our study also revealed that bevacizumab combination with the
anti-blastic doublet is correlated with a significant increase
in activated (CD8+CD62L+) CTLs, long-term effector memory
(CD8+CD27+) and central-memory (CD8+C45RA-CCR7+) CTLs. In
addition, our ex vivo investigation was on line with these findings;
in fact, antigen-specific T-cell proliferation, as well as a greater
antigen-specific Th1 response with potential cytotoxic activity,
was recorded only in PBMCs derived from patients who had
received the mPE doublet plus bevacizumab. On the other hand,
the homologs T cells lines derived from mPE group showed a poor
antigen-specific proliferative response and a non-cytotoxic, pro-
humoral Th2 response. In our experiments, the antigen-specific
IL10 production suggests an immune-response as a possible
inhibitory feed-back response to antigen-specific over-
stimulation.36 In the present study, we were unable to identify
possible effects of mPEBev on MDICs expression in patients’ blood
samples; on the contrary, mPEBev regimen was able to increase
the percentage of activated and mature myeloid derived DCs, as
shown by a significant increase in CD83+ and CD80+-positive cells.
The latter findings suggest that VEGF deprivation can improve
antigen presentation by promoting DC expression and activation;
this, in turn, can induce the expansion of the effector T-cell
compartment with long-term memory and high-tumor-specific
killing activity and enable to achieve distant lymph-nodes and
tumor sites, producing the chemotactic chemokines 19 and 21
recognized by the chemokine receptor (CCR)-7 expressed on the
surface of these CTLs.39,40
It is commonly accepted that in condition of hypoxia and
chronic inflammation, granulocyte produce high levels of VEGF
that, in turn, by interacting with the FLT-1/VEGFR1, promotes neo-
angiogenesis for tissue repair, and the expansion and maturation
Figure 5. (a) A flow cytometric analysis concerning the expression of CD8+Ki67+ cells in T-cell cultures undergone multiple in vitro stimulation
with IRIV and derived from the PBMCs of normal donors (ND) or mNSCLC patients isolated at the baseline ( ) and after four treatment courses
( ) with the mPE doublet alone or combined with bevacizumab (mPEBev). Further panels describe the ELISA dosage of Th1 (IFNɣ, TNFα ) and
Th2 (IL4 and IL10) cytokines in the supernatant of T-cell cultures in vitro stimulated with SEB (b), IRIV (c) and TSPP (d), and derived from the
PBMCs of normal donors (ND) or mNSCLC patients and isolated at the baseline ( ) or after four treatment courses ( ) with the doublet alone
(mPE) or combined with bevacizumab (mPEBev). Results are expressed as fold induction relative to baseline indicated as 1 (± S.E.). Asterisk
represents statistical significance to the correspondent baseline values (*Po0.05).
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of additional myeloid cells.41,42 MDICs family is a blood cell
lineage population dependent by VEGF, IL10 and IL-13 levels.
Once activated, MDICs may exerts a powerful immunological
inhibitory activity affecting the activation of both DCs’ and
antigen-specific CTLs’ precursors.41,42 On this light, we
have previously reported that VEGF deprivation, induced by the
mPEBev regimen, is associated to a progressive decrease in the
number and maturation of neutrophils.41,42 In the present study,
we were unable to demonstrate possible treatment-associated
changes in the percentage of CD14−CD15+CD11b+CD66b+ MDICs
in patients' peripheral blood, mostly due to the significant
heterogeneous results obtained in these patients' samples.
However, the present finding do not exclude that the inhibitory
activity of these cells is repressed by VEGF deprivation, as
suggested by the results on DC activation, CTL response and
ex vivo results on antigen-specific CTLs. Additional experiments
are presently ongoing to evaluate the effective role of MDICs
deactivation in patients receiving bevacizumab and platinum
based doublets. In previous studies, in line with the results of
other authors, we have observed that patients receiving mPEBev
treatment may develop parenchimal fibrosis and cavitations in
lung sites apparently not involved by the tumor and more rarely
in lethargic encephalitis.23–26,43,44 These events can be, at least in
part, explained by the occurrence of autoimmunity or of excessive
immune-effector-mediated response to subclinical viral
infections.43,44 On the basis of these results, we can hypothesize
that the immunological effects associated to bevacizumab
administration could, at least theoretically, synergize with
chemotherapy in enhancing the final antitumor effect in mNSCLC
patients. In this light, it has been proposed that necrosis, massive
antigen release and the formation of apoptotic bodies, caused by
cytotoxic drugs in tumor tissues, could decrease the levels of
immune-response inhibition mediated by PD-1/PD-1 ligand
interactions. The latter effect can, in turn, cause a powerful
immunological danger signal, thus leading to an increase of
efficient antigen-specific CTL response with long-term memory.
This observation has represented the bases for the combination of
chemotherapy and/or radiotherapy with immune-adjuvant cyto-
kines, active-specific immunotherapy and checkpoint inhibitors, in
the treatment of human malignancies.44–51 Previous results from
us and others have already shown preclinical evidence that both
chemotherapy and bevacizumab administration may affect
MDICs and Tregs’ expansion,
50,51 whereas the present study
demonstrate that it may also improve DC maturation and enhance
CTL response, thus producing a more complex and efficacious
antitumor effect. Moreover, the long-term effects of bevacizumab
on the effector memory T cells and Th1 lymphocyte subsets
could have a positive impact on patients’ survival because
the antitumor specific immune-response can be auto-sustained
after the end of the treatment.50,51 In conclusion, bevacizumab
immune-modulating effects, together with its anti-angiogenetic
properties, could equally contribute to define the ultimate
antitumor effects in cancer patients, thus increasing their survival.
Our results suggest that the mPEBev regimen promotes the best
conditions for an efficient antigen-specific CTL response and
makes the mPEBev a potential candidate regimen to be assessed




The study protocol code #BEVA2007 was performed in accordance to the
good clinical practice guidelines and was approved by the Bioethics
Committee of the University of Siena. All patients provided a written
informed consent. The inclusion criteria were: histological diagnosis of
mNSCLC, performance status (ECOG) from 0 to 2, normal renal and hepatic
function, WBC count 42500/mm3, hemoglobin 49 g/dl, platelet cell
count 490 000/mm3 and normal cardiac function. The exclusion criteria
were: central tumors with high risk of bleeding (excavated with large
necrosis and infiltration of large arterial and venous structures) for
bevacizumab use, a history of other severe cardiovascular disease,
arrhythmia, second malignant tumors and signs of active infections.
Treatment schedule
All of the patients received every 3 weeks, iv. cisplatinum (30 mg/sqm) on
days 1-3, daily oral etoposide (50 mg) on days 1–15 and bevacizumab at
5 mg/kg on the day 3, for a maximum of four consecutive cycles.
Subsequently, all patients who did not show a progression of disease,
received erlotinib administration (150 mg/die) until progression of disease,
starting 1 week after last chemotherapy course.
Biological analysis and blood sampling
Peripheral blood samples (10 ml) were withdrawn at baseline and 1 h
before any treatment cycle, for either serum and PBMC isolation. Serum
derived from standard peripheral blood centrifugation and PBMCs
obtained by Ficoll-Hypaque (Celbio S.P.A., Italy) gradient separation
medium, form heparinized blood samples, were immediately frozen and
stored as described in previous studies.52 Lymphocytes, platelets,
neutrophils and monocytes were evaluated by hemocytometric cell
counts, while their feature was evaluated by microscope analysis. Flow
cytometry was perfomed on patients’ PBMCs by carrying out standard
multicolor immuno-cytoflurimetric analysis with conjugated anti-CD3, CD4,
CD8, CD27, CD62L, CD19, CD16, CD56, CD25, FoxP3, CCR7, CD45Ra, CD11b,
CD11c, CD14 and CD15, all purchased by eBioscience, USA.
Bio-Plex assay
Blood samples were collected from a peripheral vein at baseline and after
3 treatment courses and kept on ice. Serum was collected by centrifuga-
tion (3000 r.p.m. for 10 min at 4 °C), aliquoted and stored at − 80 °C until
analyzed. A multiplex biometric ELISA-based immunoassay, containing
dyed microspheres conjugated with a monoclonal antibody specific for a
target protein was used according to the manufacturer’s instructions
(Bioplex, Bio-Rad Lab., Inc., Hercules, CA, USA). Soluble molecules were
measured using either commercially available kits or customized kits for
the evaluation of the following cytokines: Interleukin(IL)4, IL8, IL10, IL12,
IL17, IFNγ, TNFα, VEGF, granulocyte colony-stimulating factor, angiopoie-
tin-2, HGF, PECAM-1, Leptin, PDGF.BB and Follistatin. Each experiment was
performed in duplicate using the same procedure described in previous
papers.53 Serum levels of all proteins were determined using a Bio-Plex
array reader (Luminex, Austin, TX, USA) that quantifies multiplex
immunoassays in a 96-well plate with very small fluid volumes. The
analyte concentration was calculated using a standard curve, with software
provided by the manufacturer (Bio-Plex Manager Software, Hercules, CA,
USA).
In vitro stimulation of patients’ PBMC
PBMCs were isolated from four different patients who had received the
mPEBev regimen and three patients who had received the mPE treatment.
Blood samples taken at baseline and after three treatment courses were
seeded in 24-multi-well plate at the final concentration of 106 cells/ml in
complete medium (AIM-V) with 5% heat inactivated human AB serum.
As previously described,30 PBMCs were in vitro stimulated every 15 days
with autologous irradiated PBMCs loaded with SEB (1 μg/ml), IRIV (5 μg/ml)
or TSPP (10 μg/ml), in complete medium containing IL4 (0.5 ng/ml),
granulocyte macrophage colony-stimulating factor (15 ng/ml) for 5 days,
and then followed by 10 days of culture in the presence of IL2 (25 UI/ml)
before being restimulated with the same modalities.
Flow cytometry was performed on T-cell lines after three IVS with IRIV,
whereas cytokine assays were performed by Bioplex analysis on the
supernatant T cells after 4 IVS with the specific antigen.
Statistical analysis
The between-mean differences were statistically analyzed using Stat View
statistical software (Abacus Concepts, Berkeley, CA). The results were
expressed as the mean± S.D. of four determinations made in three
different experiments, and the differences determined using the two-tail
Student’s t-test for paired samples. A P-value of 0.05 or less was considered
statistically significant.
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